Affordable Access

deepdyve-link
Publisher Website

Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma.

Authors
  • Valero, Cristina1
  • Pardo, Laura1
  • Sansa, Aina1
  • Garcia Lorenzo, Jacinto1
  • López, Montserrat1
  • Quer, Miquel1
  • León, Xavier1, 2
  • 1 Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. , (Spain)
  • 2 Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. , (Spain)
Type
Published Article
Journal
Head & neck
Publication Date
Nov 21, 2019
Identifiers
DOI: 10.1002/hed.26010
PMID: 31750591
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Inflammation and immune evasion are associated with carcinogenesis. Systemic Inflammation Response Index (SIRI) has been proposed as a pretreatment peripheral blood biomarker. The aim of this study is to analyze its prognostic capacity in head and neck squamous cell carcinomas (HNSCC). We performed a retrospective study in 824 patients with HNSCC. SIRI was calculated by neutrophils*monocytes/lymphocytes. Using a recursive-partitioning analysis considering disease-specific survival (DSS) as dependent variable, three categories were defined according to SIRI value. Males, patients with history of toxic consumption, oropharyngeal or hypopharyngeal tumors, and advanced tumors had a significantly higher SIRI value. As SIRI increased, a significant decrease in DSS was observed. In a multivariable analysis, SIRI was an independent predictor of DSS. Moreover, SIRI was a significant predictor of local, regional, and distant recurrence-free survival. SIRI has independent prognostic capacity in HNSCC. Patients with higher SIRI have a significant decrease in DSS. © 2019 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times